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COVID-19 is characterized by an infectious pre-
symptomatic period, when newly infected individuals
can unwittingly infect others. We are interested
in what benefits facemasks could offer as a non-
pharmaceutical intervention, especially in the settings
where high-technology interventions, such as contact
tracing using mobile apps or rapid case detection
via molecular tests, are not sustainable. Here, we
report the results of two mathematical models and
show that facemask use by the public could make
a major contribution to reducing the impact of the
COVID-19 pandemic. Our intention is to provide
a simple modelling framework to examine the
dynamics of COVID-19 epidemics when facemasks
are worn by the public, with or without imposed
‘lock-down’ periods. Our results are illustrated for
a number of plausible values for parameter ranges
describing epidemiological processes and mechanistic
properties of facemasks, in the absence of current
measurements for these values. We show that, when
facemasks are used by the public all the time (not
just from when symptoms first appear), the effective
reproduction number, Re, can be decreased below
1, leading to the mitigation of epidemic spread.
2020 The Authors. Published by the Royal Society under the terms of the
Creative Commons Attribution License http://creativecommons.org/licenses/






Under certain conditions, when lock-down periods are implemented in combination with
100% facemask use, there is vastly less disease spread, secondary and tertiary waves are
flattened and the epidemic is brought under control. The effect occurs even when it is assumed
that facemasks are only 50% effective at capturing exhaled virus inoculum with an equal
or lower efficiency on inhalation. Facemask use by the public has been suggested to be
ineffective because wearers may touch their faces more often, thus increasing the probability of
contracting COVID-19. For completeness, our models show that facemask adoption provides
population-level benefits, even in circumstances where wearers are placed at increased risk. At
the time of writing, facemask use by the public has not been recommended in many countries,
but a recommendation for wearing face-coverings has just been announced for Scotland. Even
if facemask use began after the start of the first lock-down period, our results show that
benefits could still accrue by reducing the risk of the occurrence of further COVID-19 waves.
We examine the effects of different rates of facemask adoption without lock-down periods and
show that, even at lower levels of adoption, benefits accrue to the facemask wearers. These
analyses may explain why some countries, where adoption of facemask use by the public is
around 100%, have experienced significantly lower rates of COVID-19 spread and associated
deaths. We conclude that facemask use by the public, when used in combination with physical
distancing or periods of lock-down, may provide an acceptable way of managing the COVID-
19 pandemic and re-opening economic activity. These results are relevant to the developed as
well as the developing world, where large numbers of people are resource poor, but fabrication
of home-made, effective facemasks is possible. A key message from our analyses to aid the
widespread adoption of facemasks would be: ‘my mask protects you, your mask protects me’.
1. Introduction
The current COVID-19 pandemic, caused by the virus species severe acute respiratory syndrome-
related coronavirus, named SARS-CoV-2 [1], has stimulated considerable controversy over the
potential benefits of facemask use by the public and the timing of the initiation and termination
of ‘lock-down’ periods. We define ‘facemask’ here to mean a protective covering for the nose and
mouth, designed to interfere with airborne pathogen transmission.
Clear answers to the questions surrounding facemask use are required urgently because they
could inform national governments’ decisions and so prevent substantial loss of life, which
might be avoided with this very ‘low’-level/inexpensive technology, and minimize the risk of
health systems being overwhelmed with consequent high mortality rates of medical practitioners,
front-line essential workers and those involved in healthcare sectors around the globe. It is also
possible that this low-level technology, including home-made masks, could reduce the severe
global economic impact of COVID-19, which has the potential to cause billions of people to suffer
shortened life expectancy because of a reduced standard of living [2].
SARS-CoV-2 is similar to other respiratory pathogens in that airborne transmission occurs
by inhaling droplets loaded with SARS-CoV-2 particles that are expelled by infectious people
who are talking/coughing/sneezing [3,4]. This is most likely to occur in poorly ventilated areas
where droplets or mist particles can accumulate and be inhaled [5–7]. Infection can also occur
through the mucous membranes of the head (eyes, nose and mouth), when SARS-Cov-2 particles
are picked up on the hands and then transferred to the head by face-touching behaviours.
The currently available control measures to combat SARS-Cov-2, therefore, include: physical
distancing, population lock-down periods, good sanitation/hand washing/surface disinfecting,
good ventilation, facemask and visor protection, as well as diagnostics followed by contact tracing
and quarantine of infected and exposed individuals.
There is a wide range of dynamic-simulation, individual-based and statistical models that
are being used to analyse COVID-19 data. Many of these models, however, are complex, so





intention here is to provide a simple modelling framework to examine the probable effectiveness
of facemask wearing in combination with lock-down periods on the dynamics of COVID-19
epidemics. This involves scaling from individual behaviour to the level of populations to enable
conclusions to be drawn about the effectiveness, or otherwise, of wearing facemasks to reduce the
spread of SARS-CoV-2.
There is an extensive literature describing the dynamics of exhalation of virus from infected
individuals (e.g. velocity, reach, separation into small and large droplets) [16,17] with analyses
and models that focus on the individual. Here, we approach the key questions of this article by
linking the effects of facemask wearing on the individual processes of SARS-Cov-2 transmission
with population-level models to assess the effectiveness, or otherwise, of facemask adoption
in combination with lock-down periods under different scenarios. We provide a framework
for objective recommendations that could reduce the risks of future waves of the COVID-19
pandemic. In addition, we provide a synthesis of current knowledge and identify key areas of
missing information/data that would be required to refine parameter values affected by facemask
interference in SARS-CoV-2 transmission processes.
We first use an agent-based branching process model [18] to ask the simple question:
given the high infectiousness of SARS-CoV-2, what level of facemask adoption by the public,
associated with what level of facemask efficacy, would be required to reduce the effective
reproduction number (Re) to below 1? In our second model, we adapt a conventional susceptible–
infected–removed (SIR) compartmental model [19,20] with the extension of including ‘free-living’
inoculum. The latter is shed from both pre- and post-symptomatic infectious individuals by
talking, coughing and sneezing to generate virus-bearing droplets and a reservoir of SARS-CoV-2
particles on surfaces, known as fomites.
At the start of the pandemic, the World Health Organization (WHO) did not advocate
facemask wearing by the public owing to concerns over efficacy and the shortage of masks
and other personal protective equipment (PPE) for health workers. We argue that the lack of
experimental population-based data on facemask use [21] cannot be equated with facemask
ineffectiveness, particularly when it is accepted that patients with other respiratory diseases such
as influenza have been recommended to wear facemasks to limit virus-particle-laden droplet
spread. Influenza has different dynamics from SARS-CoV-2, including a lower effective value for
transmissibility [22], yet Yan et al. [22], for example, also reported that an 80% compliance rate for
respiratory protective devices eliminated an influenza outbreak. A modelling study associated
with the influenza management strategy [22] was also useful to public-health officials making
decisions concerning resource allocation or public-education strategies. An earlier study [23] also
concluded that household transmission of influenza could be reduced by the use of facemasks
and intensified hand hygiene, when implemented early and used diligently. In addition, concerns
about the acceptability and tolerability of the interventions should not be used as a reason against
their recommendation.
Our models can be used to consider the transmission dynamics from the perspective of the
susceptible individual, including the possibility that facemask wearing may increase the risk
of transmission (e.g. through adjustments to facemasks that result in increased touching of the
face, with associated risk of inadvertent transmission of SARS-CoV-2) from airborne and fomite
reservoirs. We also examine changes in parameter values across plausible ranges and seek to
identify the likely range of effectiveness of facemask wearing, in association with population lock-
down. In the absence of robust and reliable estimates for critical parameters, this approach can be
used to provide simulations over a wide range of values and also to highlight where improved
epidemiological parameter estimates are required. In this spirit, we propose, therefore, that the
work presented here provides an objective and logical approach to examining the key question
of whether, or not, the public should be advised to wear facemasks in the current COVID-19
pandemic. Our results hold for low-, middle- and high-income countries.
We can ask the following questions at a population level. (i) How effective and how frequently
would facemasks need to be used by the public to ‘flatten the disease progress curve’? (ii) How





(iii) How does the timing of the implementation of lock-down periods and facemask adoption by
the public influence the models’ outcomes?
2. Methods
We use two complementary modelling approaches to test the effectiveness of facemask wearing
by sections of the population in reducing the transmission rate of SARS-Cov-2 and hence in
reducing the effective reproduction number, Re (the expected number of new cases caused by
a single infectious individual at a given point in the epidemic). The first model uses a branching
process to investigate the reduction in transmission by wearing facemasks, in order to assess
the likely effectiveness of two control variables in reducing Re for the pathogen. The control
variables are the proportion of the population wearing facemasks (essentially the probability
that an individual wears a mask on a given day) and the effectiveness of the mask in reducing
transmission (which relates to a range of masks that extend from crude porous coverings [24,25]
to masks of clinical standard [26,27]). The purpose of this model is to identify whether or not there
are clear parameter ranges in which the two control variables could reduce Re sufficiently to be
expected to slow or stop the epidemic spread. We simulate the consequences of wearers using
facemasks routinely, or only after the onset of symptoms.
In the second model, we adapt the common SIR formulation, to which we add free-living
SARS-CoV-2 particles transmitted by inhalation from droplet inoculum and by touch and contact
with facial orifices from the fomite inoculum deposited on surfaces (§2b(i)). The model is
used to consider the likely impacts of facemask wearing in combination with phases of lock-
down, interspersed with release from them. The flexible structure of this modelling framework
importantly allows a distinction to be made between the potential for facemasks to reduce
transmission from infected individuals (before and after symptom expression) and the protection
conferred by facemasks on susceptible individuals [28]. The latter may be positive, whereby the
facemask reduces inhalation of inoculum. It may also be negative; for example, where frequent
manual adjustment of the facemask increases the probability of transmission. Our intention is
to provide a flexible, yet comparatively simple modelling framework to test hypotheses about
facemask wearing in combination with other epidemic strategies, which also allows scaling from
individual behaviour to population consequences. SARS-CoV-2 is a new disease to humanity so,
given the gaps in our knowledge about certain parameter values, the inferences should be viewed
in this light. Further details of the models are summarized below and the code is available at
https://github.com/camepidem/COVID-19_PRSA.
(a) Branching process transmission model
We model SARS-CoV-2 transmission as a branching process model, where the number of
secondary cases caused by one infectious individual is drawn from a negative binomial
distribution with the mean equal to the product of the reproduction number (R0, the number
of individuals infected by the introduction of a single infectious individual to an otherwise
susceptible population) and dispersion parameter k, and the time of each new infection dependent
on the incubation period of the primary case and the relative infectiousness β(t) [18]. The random
branching process has been used for many COVID-19 analyses [29–37]. Given the wide variation
in quoted values for COVID-19’s R0 [38], we consider two cases: R0 = 2.2 and k = 0.54 [36]; and
R0 = 4.0, which is in line with the recent estimate of around 3.87, which is based on the initial
growth of observed cases and deaths in 11 European countries [30].
We assume that time-varying relative infectiousness follows a shifted gamma distribution,
reaching a peak 1–2 days before onset of symptoms [39] and then decreasing monotonically
[40,41] (figure 1). The incubation period is assumed to be lognormal with meanlog 1.43 and s.d.log
0.66 [39].
To implement control by wearing facemasks, we assumed that a proportion of the population
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Figure 1. Distributionof asymptomatic and symptomatic infectiousness of COVID-19-infected individuals, used in thebranching
process [39]. Horizontal lines show the average infectiousness per time unit for the asymptomatic stage (orange) and the
symptomatic stage (red).
is reduced by (1 − γ ), where γ is the effectiveness of a facemask in reducing transmissibility. We
explore two scenarios: wearing a facemask after the onset of symptoms and wearing a facemask
all the time.
(b) Susceptible–infected–removed model with free-living inoculum
(i) Model description and formulation
The model structure is summarized in figure 2. There are two populations, facemask wearers and
non-facemask wearers, each comprising individuals in the following categories: susceptible (S);
exposed, i.e. latently infected (E); asymptomatically infectious (IA); symptomatically infectious
(IS); and removed (R). The removed class includes individuals who recovered from infection
and those who died. Susceptible individuals can become infected by coming into contact with
inoculum produced by individuals infected with SARS-CoV-2. We separate inoculum creation
by infectious individuals, which gives rise to free-living inoculum, from inoculum uptake and
infection of susceptible individuals. The inoculum can either be acquired by inhaling from
transient droplet (D) forms in the air [42] or by contact with a decaying reservoir of inoculum
deposited by infected individuals in the environment as fomites (F) [42], which can survive for
up to 72 h on some surfaces [43]. There is a rapid deposition of droplet inoculum [44–46] with
a slower decay of fomite (figure 2). There are two pairs of transmission rates, therefore: βA and
βS for creation of inoculum by asymptomatic and symptomatic individuals, respectively, and βD
and βF for uptake and infection of susceptible individuals from the droplet and fomite inoculum,
respectively. Facemask wearing affects some or all of these parameters (cf. mi in figure 2).
Facemasks reduce the amount of droplet inoculum escaping from infectious individuals [25]
by capturing a proportion of droplets within the mask (mA, ms < 1). Facemasks also reduce the
amount of droplet inoculum inhaled by susceptible individuals by capturing a proportion of
droplets in inhaled air and hence reducing the uptake transmission rate (βD) by mD (figure 2).
We assume initially that masks have a negligible effect on the risk of contacting inoculum from
surfaces (βF) with mF = 1. The model does, however, allow for the fact that wearing a mask
could increase infection risk from fomite infection (mF > 1); for example, through more frequent
touching of the face when adjusting the mask. We note that significant PPE, such as a full face-
hood, could act to reduce the risk of fomite infection (mF < 1). In addition, sanitation interventions

















exposed asymptomatic symptomatic removed














Figure 2. Schematic of the SIR framework model for interacting populations of facemask and non-facemask wearers, in which
transmission pathways are distinguished between (i) inoculum creation by asymptomatic and symptomatic infected individuals
and (ii) uptake/infection from droplet and fomite inoculum. Themodel can be adapted further to allow for cycles of population
lock-downs.
additional cleaning of surfaces or the use of quicker self-sterilizing surfaces can be modelled
via reducing the lifespan of fomite inoculum (τF). Here, we restrict our analysis to the effects
of facemasks and lock-down periods.
The model is formulated and solved as a simple deterministic differential equation model,
summarized below for completeness. We note that the model can be recast readily in
stochastic form with transition probabilities. It is also simple to divide the target country into
metapopulations in which the contact rates differ, for example among cities and rural areas or
between age classes in the population, and to spatially partition the population with localized
inoculum pools. Here, we use the model to look at orders of magnitude for how facemask wearing
complements a major control strategy that involves lock-down of a proportion of the population.
We simulate this by assuming that lock-down reduces the transmission rates (β i, i = A,S,D,F) by
a fixed proportion, q. It reduces the inoculum produced by infectious individuals in public areas
and thus reduces the inoculum available in the D and F pools, and additionally reduces the time
spent in contact with that inoculum by susceptibles. Thus, in the model, lock-down works to




= −(βFmFF + βDmDD)S,
dE
dt







































Given a population size of N (large, R0), all susceptible and the introduction of one exposed
individual:
Total droplet inoculum produced
DTotal = βAτA + βSτS.
Total infections caused by droplet (D) and fomite (F) inoculum
ID = βDNDTotalτD,
IF = βFNFTotalτF.
Thus R0, i.e. total infections caused by the initial introduction (noting DTotal = FTotal)
R0 = (βDτD + βFτF)DTotalN,
R0 = (βDτD + βFτF)(βAτA + βSτS)N.
Given the proportion of R0 due to droplets, μ = βDτD(βDτD+βFτF) , we obtain a relation between the

























A summary of the model parameters and default values for the modified SIR compartmental
model with free-living inoculum is given in table 1.
(ii) Additional assumptions and knowledge gaps
A key assumption of the model is that those people who have been infected and have recovered
have immunity to further infections. At present, there are no experimental data to validate
this assumption [48] and it is widely accepted that the four related, seasonal coronaviruses,
responsible for up to 30% of common colds, cause illness repeatedly, even though people have
been exposed to them throughout their lives.
We also make assumptions and simplifications about the effectiveness of facemasks because
there is a wide range of possible designs [49]. In general, however, the important fact here is
that inoculum release is principally through the mouth, which the facemask covers effectively, so
this is a key point is estimating the facemasks’ efficacy at catching exhaled inoculum. Evidence
from the literature shows that the filtration efficiency of different cotton-fabric facemasks varies
between 43% and 94% in controlling the passage of bacteria [47], which travel in moisture
droplets in the same way as viruses. Droplet-blocking efficiency of fabric samples was shown
to be 90–98% for 100% cotton T-shirt, dishcloth and silk shirt, which was as high as for fabric
material used for the production of a three-layered commercial medical mask [50]. More recent
research showed that surgical facemasks significantly reduced the detection of influenza virus
RNA in respiratory droplets and coronavirus RNA in airborne droplets and it was concluded
that surgical facemasks could prevent coronavirus transmission from symptomatic individuals
[51]. In addition, facemasks capture the larger droplets most effectively, and these carry most of
the virus load (a droplet with twice the diameter has eight times the weight and virus content).
Further qualitative evidence of the effectiveness of facemasks at catching exhaled infection agents
is the universal acceptance of the need for surgeons to wear a facemask when operating to avoid
the infection of the wound on which they are working. We assume, therefore, that facemask
effectiveness in exhalation is probably well above 50% on average, but probably poorer on
inhalation; we justify this in terms of the difference in dynamics between airflow coming out





Table 1. Model parameters and default values for the modified SIR compartment model with free-living inoculum. Note that
our inferences, choices of parameters and population sizes do not relate to healthcare environments, as would be found in
hospitals, where inoculum levels may be extremely high and personnel already wear appropriate PPE.
parameter description default value source
N population size 60 million approximate mainland GB population size
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
R0 basic reproductive rate 4 [30]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
βA inoculum release rate of asymptomatic
infectious individuals
2.71 unit inoculum per
day per capita
relative toβS [39]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
βS inoculum release rate of symptomatic
infectious individuals
1 unit inoculum per
day per capita
arbitrarily defined, without loss of
generality
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
βD infection rate due to droplet inoculum 4.46× 10−5 per unit
inoculum per day
fitted subject to default values of R0,
μ and N
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
βF infection rate due to fomite inoculum 2.58× 10−9 per unit
inoculum per day
fitted subject to default values of R0,
μ and N
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mA reduction in inoculum release rate of
asymptomatic individuals for mask
wearers
0.5 arbitrarily set in the absence of detailed
data on individual-based transmission;
consistent with lower ranges quoted by
Furuhashi [47]; van der Sande et al. [25]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mS reduction in inoculum release rate of
symptomatic individuals of mask
wearers
0.5 arbitrarily set in the absence of detailed
data on individual-based transmission;
consistent with lower ranges quoted by
Furuhashi [47]; van der Sande et al. [25]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mD reduction in inoculum infection rate due to
droplet inoculum for mask wearers
0.5 arbitrarily set in the absence of detailed
data on individual-based transmission
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
mF reduction in inoculum infection rate due to
fomite inoculum for mask wearers
1.0 arbitrarily set in the absence of detailed
data on individual-based transmission
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
q reduction of transmission rates from
lock-down of the population
0.5 [30] showing Re dropped from∼4 before
to∼1 after lock-down
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
τ E average duration between infection and
onset of asymptomatic infectiousness
3.8 d [39]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
τ A average duration between onset of
asymptomatic infectiousness and first
symptoms
1.2 d [39]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
τ S average duration between first symptoms
and end of infectiousness
3.2 d [39]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
τ D average lifespan of droplet inoculum
before deposition
10 s [44–46]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
τ F average lifespan of fomite inoculum before
loss of viability
48 h [43]
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
μ assumed proportion of infections due to
droplet inoculum in the absence of
masks or other forms of control
0.5 arbitrarily set in the absence of detailed
data on individual-based transmission
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
a lit match at arm’s length compared with the impossibility of putting it out by sucking in air.
Exhaled air, therefore, is likely to go mostly through the fabric, whereas inhaled air is much more
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Figure 3. Heat maps of the effective reproduction number (Re) as a function of control parameters for two values of R0. Even
when R0 is 4.0, the best outcomes are achieved when masks are worn all the time, a high proportion of the population wear
them and their efficacy is high.
3. Results
(a) Model 1: branching process transmission
We explore how the effective reproductive number (Re), i.e. the average number of infections
generated by an infectious individual in the population, changes under a range of possible values
for the proportion of a population wearing facemasks and the efficacy of the facemasks. Figures 3
and 4 show results for simulations with the branching process model run initiated with 100
infectious individuals in generation 1 and the proportion of the population wearing a facemask
after generation 3. We distinguish between two scenarios: facemasks worn after symptoms are
expressed and facemasks worn all the time. By ‘all the time’, we mean compliance with normal
facemask procedures when in public [52], irrespective of whether or not COVID-19 symptoms are
being expressed.
Even when the initial reproductive number (R0) is 4.0, our analyses show that the best
reductions in the Re occur when facemasks are worn all the time, by a high proportion of the
population and their efficacy is high (figure 3). It is also possible (subject to the simplifying
assumptions) for Re to be brought below 1, when the public wear effective facemasks all of the
time (rather than only starting when COVID-19 symptoms appear), leading to the epidemic dying
out. These exploratory analyses from this model suggest that there are regions of parameter space
(proportion of population wearing facemasks and effectiveness of the facemasks in reducing
transmission) in which this intervention strategy could be effective. We now examine the
dynamics in more detail, with a more mechanistic model, albeit in which there is still uncertainty
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Figure 4. The effect on Re of the proportion of the population wearing a facemask. The solid line is the mean and the shaded
area shows the 95% confidence interval. By the public wearing an effective facemask all of the time (rather than just starting
when COVID-19 symptoms appear), the Re can be brought below 1, leading to the pandemic dying out.
(b) Model 2: the adapted susceptible–infected–removed compartment model
This model allows us to investigate the interactions between lock-down periods and various
percentages of facemask adoption by the public. Here, we examined the effects of changing the
proportion of people wearing masks (0%, 25%, 50%, 100%), when there are successive periods
of lock-down. Our focus here is on the potential for reducing SARS-CoV-2 transmission by
facemasks and we do not consider any other intervention besides population lock-down.
We first examine the epidemic dynamics, for different proportions of facemask wearers,
when facemask wearing is initiated at the beginning of the epidemic. The epidemic takes off
exponentially and is only slowed by the imposition of the first lock-down period, which we
assume reduces overall transmission of the virus (table 1 and figure 5a). A second wave begins
after the first lock-down is lifted, which is suppressed by the second lock-down period. By the
third lock-down period, under this scenario, everyone has become infected and the epidemic dies
down. This does assume that infected/recovered people have become immune/resistant. With
25% facemask adoption, the initial peak is flattened, but the second wave is more pronounced
(figure 5b). At 50% adoption, secondary and tertiary disease peaks occur in the second and
third lock-down periods (figure 5c). The benefits of the additional reduction in transmission rate
effected by facemasks are fairly equally divided between facemask and non-facemask wearers
(figure 5c). When 100% of the public wear facemasks, disease spread is greatly diminished and
the total numbers of ‘removed’ are substantially lower. Here, we consider an 18 month time scale,
either until the introduction of a vaccine or to the point at which sustained lock-down control
efforts are not feasible.
We next relax the assumption that facemask wearing begins from early in the epidemic when
there are just 100 detected cases (as in figure 5) and investigate the later adoption at 30, 60, 90
and 120 days. While later adoption leads to increases in the numbers of individuals who become
infected, even when implemented at 120 days after the initiation of the epidemic (figure 6), 100%
adoption of facemasks by the public (under the current assumptions: table 1 and figure 6d) stops
the occurrence of further COVID-19 epidemic waves. We also note that there are benefits to
employing facemasks even when Re has fallen below 1. For example, the number of active cases
















lock-down: start: T+45 days, duration: 90 days, 50% contact reduction, 30 days off, 4 cycles
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masks: 50% wearing, inoculum capture: 50% exhale, 50% inhale, fomite 0%
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Figure 5. The vertical, blue, dotted line indicates the time at which facemask wearing is adopted. (a) With no facemasks, the
disease progress curve increases exponentially before periods 2 and 3 and is only slowed by the imposition of the first lock-down
period. When this ends, a second wave begins, which is suppressed by the third lock-down period. By the fourth lock-down
period, everyone has become infected and the epidemic dies down. This does assume that infected/recovered people have
become immune/resistant. (b) With 25% facemask adoption, the initial three peaks are flattened, but a second, larger wave
appears in the fourth lock-down period. There are clear benefits to facemask wearers, compared with non-wearers. (c) At 50%
adoption, the disease progress curve does not take-off until after the fourth lock-down period. (d) When 100% of the public
wear facemasks, disease spread is greatly diminished and the total numbers of ‘removed’ is much lower (note the different
y-axis scale for d).
in active cases is reached, than in figure 6d, where facemasks are not adopted until later. This
faster drop in active cases could allow for an earlier lifting of lock-down. We note that, when
the number of cases is reduced to a sufficiently low level, other forms of control such as contact
tracing become more feasible.
For completeness, we analysed the effects of facemask use in the absence of lock-down or
other mitigation procedures (figure 7). We note that, in scenarios 5c and 5d, the epidemic has not
infected enough of the population to reach herd immunity in the absence of periodic lock-downs.
The long-term dynamics of these outbreaks after the relaxation of lock-down are examined in
figure 6. The default parameters remain as in table 1 and salient parameters are repeated in
figure 7. It is clear that, consistent with an epidemic with an R0 value of approximately 4 [30],
the epidemic increases exponentially, leading to very high levels of infection. Here, as elsewhere,
we assume that infection confers immunity, though that assumption can easily be relaxed by
expanding the framework with free-living inoculum to incorporate a SIRS model, where after
some time removed individuals can become susceptible again. Adoption of facemask wearing by
25% of the population decreases the level of infection in the population (figure 7b). The effects
increase with greater adoption (figure 7c,d). At 100% adoption (figure 7d), the disease progress
curve is flattened significantly and the total number of individuals infected is reduced. We note
that 100% facemask adoption without lock-down achieves a greater reduction in the final size
of epidemic, a lower ‘total removed’ and a lower peak of active cases than lock-down without
facemasks (figure 5a). These results are striking in that the benefits accrue to the facemask wearer
as well as to the population as a whole. We have assumed a reduction each in inhalation and








masks: start: T+30 days, 100% wearing, inoculum capture: 50% exhale, 50% inhale, fomite 0%
lock-down: start: T+45 days, duration: 90 days, 50% contact reduction, 30 days off, 4 cycles
masks: start: T+60 days, 100% wearing, inoculum capture: 50% exhale, 50% inhale, fomite 0%
lock-down: start: T+45 days, duration: 90 days, 50% contact reduction, 30 days off, 4 cycles
masks: start: T+90 days, 100% wearing, inoculum capture: 50% exhale, 50% inhale, fomite 0%
lock-down: start: T+45 days, duration: 90 days, 50% contact reduction, 30 days off, 4 cycles
masks: start: T+120 days, 100% wearing, inoculum capture: 50% exhale, 50% inhale, fomite 0%
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Figure 6. Effect of changing start date for facemask adoption, shown by the blue dashed line. (a–d) T + 30d, T + 60d,
T + 90d, T + 120d, respectively. The first lock-downperiod started at T+ 90d. Earlier adoption of facemasks (a) has a different
y-axis scale, because the end values of total removed are significantly lower. Even when implemented at T+120 days, 100%
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Figure7. Effects of facemask adoption in the absenceof lock-downperiods, using the same facemask-wearingproportions as in
figure 6. The vertical, blue dotted line indicates the time at which facemask wearing is adopted. (a) Default epidemic dynamics
in the absence of any intervention. (b) Twenty-five per cent facemask wearers in the population slows the overall epidemic
progression, but provides minimal reduction in final size. (c) Fifty per cent adoption of facemasks further slows epidemic
progression and slightly decreases final size, with benefits distributed fairly evenly between mask and non-mask wearers. (d)
One hundred per cent adoption with 50% reduction in inhalation and exhalation leads to flattening and delay of the disease
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Figure 8. The per capita probability of infection in relation to the proportion of the population wearing facemasks and the
negative effects of fomite infection, owing to poor compliance. The blue dashed line represents the individual probability of
infection when no one wears a facemask. (a) When the fomite parameter is at 0% and droplet exhalation and inhalation
are both reduced by 50% for facemask wearers (good compliance and facemask), facemask wearers benefit more than non-
facemask wearers and the probability of infection drops with increasing proportion of the population wearing facemasks, and
is always lower for both facemask wearers and non-wearers than if nobody wears a mask. (b) When facemask wearing incurs
a susceptibility penalty, with the fomite susceptibility increased by 100% and a 50% reduction in droplet exhalation, but no
effect on droplet inhalation (bad compliance and facemask), there is a net benefit to the population, but the mask wearers are
personally worse off until about 65% of the population is wearing them, when even the facemask wearers become better off
than if nobodywears facemasks. (c) When compliance and facemask usage are very bad (fomite susceptibility increase of 300%
and 50% droplet exhalation reduction), non-facemask wearers are at an advantage but, counterintuitively, until about 80%
facemask adoption, there is still a small net benefit to the population as awhole, although a larger benefit to non-maskwearers.
Note the different axis scales in each subplot, e.g. the facemasks in (a) are able to deliver a 40% reduction in population-level





It is also instructive to consider the per capita probability of infection in relation to the
proportion of the population wearing facemasks and the negative effects of fomite infection,
owing to poor compliance and ineffective facemasks. When the fomite parameter for infection
is at 0% (good compliance and facemask), facemask wearers benefit more than non-facemask
wearers and the probability of infection drops with increasing proportion of the population
wearing facemasks. As the proportion of mask wearers increases, the benefits to both facemask
wearers and non-facemask wearers increase (figure 8a). We see that if facemask wearing were to
incur a susceptibility penalty—with the fomite parameter increased by 100% and no protection
against droplet inhalation, while retaining the 50% reduction in droplet exhalation—there is
still a net benefit to the population. In this scenario, the mask wearers are personally worse
off until about 65% of the population is wearing masks, at which point even the facemask
wearers become better off than if nobody in the population was wearing facemasks (figure 8b).
When compliance and facemask wearing are very bad (300% increase in fomite susceptibility
with only the 50% reduction in droplet exhalation), non-mask wearers are at an advantage,
but a highly counterintuitive finding is apparent in that, until about 80% facemask adoption,
there is still a net benefit to the population as a whole, and a greater benefit for non-mask
wearers. This non-intuitive result is due to the fact that, while an individual is made much more
susceptible, this is more than counteracted by the reduced infectiousness of many individuals.
These facemask wearers are more likely to contract the disease, but less likely to infect others
(particularly non-facemask wearers) once infected. When most of the population is wearing these
facemasks, the effect of reduced infectiousness is outweighed by the fact that the majority of
the population is much more susceptible. In the unlikely eventuality of facemasks with this
property, it would be advisable to preferentially issue these masks to individuals less vulnerable
to severe complications, leaving more vulnerable individuals unmasked in order to maximize
overall benefits, while still achieving a lower level of infection within the population.
4. Discussion
The emergence of the COVID-19 pandemic has stimulated a search for possible interventions,
such as SARS-CoV-2 vaccines, but these may not be effective or become available in the near
future [53]. There has also been a lack of clarity in the thinking surrounding the potential benefits
of population-level adoption of facemasks, which could provide a cheap and effective means of
managing COVID-19 epidemics in high-, middle- and low-income countries.
Previous work used a similar mathematical model-based approach to estimate the relative
contributions of the four pathways to infection risk in the context of a person attending
a bed-ridden family member ill with influenza [54]. Our models, however, concern SARS-
CoV-2 and are focused on the population consequences of lock-down periods and facemask
adoption. Our conclusions are similar, however, in that, given the current limited information
on dose and infectivity via different exposure pathways, non-pharmaceutical interventions
should simultaneously address potential exposure via face-touching behaviour and inhalation
of virus particles. A separate study also recently analysed the effectiveness of facemasks using a
compartmental, ordinary differential equation model, albeit in a more conventional form, without
the incorporation of free-living inoculum [55]. Similarly, they concluded that facemasks were
valuable in reducing virus transmission. They also demonstrated that the relative benefit of
facemask use was greater when adopted earlier [55]. Neither Nicas & Jones [54] nor Eikenberry
et al. [55] considered facemasks in combination with lock-down periods.
We first used a relatively simple mathematical model to ascertain the potential impacts of
facemasks, given the transmission characteristics of SARS-CoV-2. Then, we used a modified SIR
model with free-living inoculum that enables distinction between SARS-CoV-2 particle shedding
and uptake/infection to integrate cycles of lock-down periods interspersed with release of the
public. Our intention here is not to reproduce detailed, realistic, individual-based simulation
models [56] but rather to introduce and analyse a simple mechanistic model that can be used to





assumptions to parametrize our models. It is understood, however, that our estimated outcomes
are influenced by these parameter ranges and values.
Our mechanistic, modified SIR model can be used to analyse any intervention that
affects transmission rates, with the advantages of separating droplet from fomite components.
This model could also readily be made more realistic and complex, by considering and
including linked subpopulations within a metapopulation, stochastic processes and allowing for
uncertainty by sampling parameters from posterior or other distributions.
Our approach is to accept that, with a new disease, it is impossible to get accurate experimental
evidence for potential control interventions, but that this problem can be approached by using
mathematical modelling tools to provide a framework to aid rational decision-making. For
completeness and objectivity, we also model a scenario where facemask adoption had negative
effects. We do consider this scenario unlikely, however, because countries where facemask
wearing is mandatory are currently experiencing relatively low numbers of COVID-19 cases and
deaths [57,58].
Both of our models show that, under a wide range of plausible parameter conditions, facemask
use by the public could significantly reduce the rate of COVID-19 spread, prevent further disease
waves and allow less stringent lock-down regimes. The effect is greatest when 100% of the public
wear facemasks. It follows that the adoption of this simple technology ought to be re-evaluated in
countries where facemask use is not being encouraged. Within the parameter regimes tested, the
models also show that, if COVID-19 is to be controlled or eradicated, early lock-down combined
with facemask adoption by close to 100% by the public needs to occur. This, of course, does not
exclude the implementation of other management interventions, such as widespread testing and
contact tracing.
The detailed conclusions that can be drawn from the branching process, transmission model
are:
(i) With a COVID-19 R0 of 2.2 and for scenarios where facemasks were worn only after onset
of symptoms, the median R0 fell below 1, if at least 95% of the population wore facemasks
(with an efficacy similar to that of N95 respirators designed to achieve a very close facial
fit and highly efficient filtration of 0.3 µm airborne particles).
(ii) When the COVID-19 R0 was higher (4.0), wearing a facemask after the onset of symptoms
still decreased the median Re to just below 2, when there was high adoption and efficacy
of facemasks.
(iii) With a policy that all individuals must wear a facemask all of the time, a median effective
COVID-19 R0 of below 1 could be reached, even with facemask effectiveness of 50% (for
R0 = 2.2) or facemask effectiveness of 75% (for R0 = 4).
Our analyses from this model are consistent with the conclusions of practical studies on the
use of professional and home-made facemasks to reduce exposure to respiratory infections among
the public, where it was concluded that any type of general mask use is likely to decrease viral
exposure and infection risk on a population level, in spite of imperfect fit and/or adherence
[25]. Other studies on respiratory virus transmission have concluded that, for compliant users,
facemasks were highly efficacious at preventing spread [59]. In a pandemic situation as now
exists, compliance is affected by perception of risk, so we would expect compliance to be high.
The detailed conclusions from the modified SIR model are consistent with those of the first
model and are that:
(iv) Lock-down periods alone do not prevent the occurrence of secondary and tertiary waves
of the pandemic occurring and these may be larger than the initial wave (figures 5 and 6).
(v) If lock-down periods are combined with 100% adoption of facemask use by the public,
the initial disease progress peak is dramatically flattened and delayed and subsequent





(vi) At the time of writing, facemask or face-covering use by the public has not been
recommended by the UK, apart from in Scotland. We considered, therefore, the effects
of varying the time of facemask adoption by the public and show that, even if facemask
use began immediately while in the first lock-down period, major benefits would still be
accrued by preventing the occurrence of further COVID-19 disease waves (figure 6a–c).
(vii) We consider a scenario, for completeness, where there are no lock-down periods and
facemask use has negative effects on the wearer (figure 8b,c). This is clearly the worst case
but we consider that, in practice, negative effects of facemask adoption are improbable,
because countries where facemask use is mandatory have relatively low COVID-19
spread and numbers of deaths. Even here, however, there is the highly counterintuitive
outcome that, although the facemasks were bad for the individuals wearing them
(because of extremely poor compliance issues and a bad facemask design), people
wearing them still provided a net benefit to the population as a whole. Here, we have
analysed a range of possible values for the enhanced risk from fomite inoculum to
facemask wearers. With currently available data, it is not possible to identify which, if
any, of these values is most likely. Further experimental work is required to address this
important aspect of facemask use.
(viii) We examined the effects of different rates of facemask adoption alone (with no lock-
down periods) by the public and show that, at lower levels of adoption, there are real
benefits to facemask wearers. This difference is reduced as the per cent facemask adoption
increases to 50%. At 100% adoption, the disease progress curve is flattened and delayed
significantly, as well as the total removed from the population being reduced. There
is, therefore, a clear incentive for people to adopt facemask wearing (figures 7 and 8a).
This is a similar conclusion to that reached by another modelling study that concluded
that facemask use by the public is potentially of high value in curtailing community
transmission and the burden of the pandemic [55].
(ix) A combination of facemask wearing and lock-down periods implemented together is
indicated to provide a better solution to the COVID-19 pandemic than either in isolation.
The models indicate that a combined mitigation strategy is required to reduce the
transmission of the pathogen to flatten and delay the disease progress curves and to
prevent repeated waves of infection. Here and elsewhere, our results are subject to the
assumptions in our models, including some arbitrary but reasonable assumptions about
key parameters, given the current state of knowledge. The effects of control measures
observed in the results presented here with R0 = 4.0 are greatly enhanced with a lower
R0.
When a new disease to humanity, caused by a pathogen, first appears and spreads, there is
an unavoidable lack of information on which to base rational control-intervention decisions. An
obvious knowledge gap is the lack of accurate data on the period when individuals are non-
symptomatic, but infectious. These data would clearly help with contact tracing, in terms of the
duration of the historical search-period required. Also, information on the size of the infectious
dose for SARS-CoV-2 is lacking, but research on SARS-CoV (the 2003 virus) showed that between
43 and 280 individual virus particles had to enter the human body in order to start an infection
[60]. Even home-made masks, washed in soapy water after each use, therefore, should reduce
fomite build-up and droplet-mediated airborne transmission. Surgical-grade masks, however,
would probably be required to reduce transmission by droplets containing viral inoculum, as
was reported for the influenza virus [61].
In the current COVID-19 pandemic, one solution to this dearth of information has been to
advocate implementation of the precautionary principle on interventions, which can be defined as
‘a strategy for approaching issues of potential harm, when extensive scientific knowledge on the
matter is lacking’. Evidence on the efficacy and acceptability, or otherwise, of facemasks to combat
respiratory disease spread, for example, is sparse and contested [62], but deaths in many countries





precautionary principle approach would be to encourage populations to adopt facemask wearing
immediately, given that facemasks are considered essential PPE for front-line healthcare workers
and that ‘we have little to lose and potentially something to gain from this measure’ [63].
Our modelling framework highlights the urgent need to translate individual-based research
on coughing, sneezing and exhaling into SARS-CoV-2 transmission rates, as shown in figure 2.
One way to do this is to identify viral loads of SARS-CoV-2 that are required for infection
and also to quantify the dispersal of particulate inoculum. That would also have a bearing on
social distancing advice where, to date, the identification of 2 m is arguably arbitrary. In a study
investigating environmental contamination by SARS-CoV-2 from a symptomatic patient wearing
an N95 facemask, no SARS-CoV-2 particles were detected on the front surface of the facemasks
worn by the study’s physicians [65]. Other recent evidence on facemasks for reducing SARS-
CoV-2 transmission is provided by an epidemiological investigation where a patient transmitted
COVID-19 to five people in one vehicle when he did not wear a facemask. In a later journey, no
one was infected in the second vehicle when he wore a facemask [5].
Although our modelling framework demonstrates that, under certain conditions, facemask
adoption by entire populations would have a significant impact on reducing COVID-19 spread,
there are additional human factors and obstacles that may prevent the implementation of this
policy or a directive being issued at a governmental level. The most important of these is probably
the perceived lack of availability of efficient facemasks (N95 respirators) and the view that these
should and must be reserved for front-line medical workers.
In emergency situations such as this where there are acute PPE shortages, however, it would
be pragmatic and acceptable for people to improvise and fabricate their own solutions to the
problem [25,49,66]. The natural mechanics of filtration are that larger droplets are captured more
effectively. So, it can safely be assumed that droplets in the 1 µm plus range will be almost
completely eliminated by such an informally made mask. This is very important because a 2 µm
droplet has a thousand times the mass of a 200 nm droplet, and a 20 µm droplet has a million
times the mass of a 200 nm droplet, the virus load being proportional to the mass. The larger
the droplets, the more important it is to capture them, and even a home-made mask will do this
very well. There are also experimental data, for instance, that show that home-made facemasks
consisting of one facial tissue (inner layer on the face) and two kitchen paper towels as the outer
layers achieved over 90% of the function of surgical mask in terms of filtration of 20–200 nm
droplets [25]. These facemasks are also disposable, so would clearly provide a pragmatic solution
to the problem, and there are many sites now on social media that provide clear instructions on
facemask making and safe use [49].
Our analysis indicates that a high proportion of the population would need to wear facemasks
to achieve reasonable impact of the intervention. In Hong Kong, 99% of survey respondents
reported wearing facemasks when outside of their home [67]. Another human factor that may
reduce facemask adoption in Western countries is cultural, because the use of facemasks is not
common in public, or there is an implication that the facemask wearer considers others as a threat.
In the current emergency, however, it is necessary to change this view, which could be achieved if
the message conveyed by a facemask was ‘my facemask protects you, your facemask protects me’.
Indeed, it is probable that making facemasks into fashion items may be another route to changing
the culture surrounding facemask use in public. A further positive effect from this cultural change
would be to reinforce the message that it is necessary to keep to a safe distance from one another.
This educational message could be conveyed easily by the government and popular press.
While our mathematical models indicate the need for improved parameter estimates,
especially for β i and mi, but also for the intrinsic epidemiological parameters (τ i) and decay
rates for droplet inoculum and fomite, they have also indicated some important interactions
with respect to timing of interventions in relation to the periodicity imposed on the dynamics
by periods of lock-down. Our exploratory analyses when modelling the initiation of facemask
adoption before, during and after an initial lock-down period indicate that the precise balance
of infecteds and susceptibles upon release from lock-down can have profound, counterintuitive





individuals in the population. This and further analyses of the benefits to facemask and
non-facemask wearers are the subject of further research.
Potential extensions to the modelling framework presented here include the extension to
a metapopulation, spatially partitioning areas of high and low contact risk, as well as the
incorporation of human behavioural shifts dependent on an individual’s perceived risk of disease,
adoption fatigue or inconsistent adoption.
Despite the potential for facemasks to reduce SARS-CoV-2 transmission, there does not appear
to be any focus on investing efforts in properly designed studies on facemasks, or evaluating large
populations including ‘at risk’ patients and in a variety of communities. We argue that these are
required urgently, and our modelling framework can readily be adapted to incorporate any new
data that become available.
In summary, our modelling analyses provide support for the immediate, universal adoption
of facemasks by the public, similar to what has been done in Taiwan, for example, where
production will soon reach 13 million facemasks daily, with well-developed plans for N95
respirator production in the pipeline [68]. Our analyses indicate that actions to facilitate this in
the UK should include clear instructions on the fabrication and safe use of home-made masks,
as well as accompanying governmental policies to increase swiftly the availability of medical
standard surgical, or N95 respirators, to the public.
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